First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor - Wikidata - wikimedia - TriplyDB

First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor

First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor

http://www.wikidata.org/entity/Q57217646

about

Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.Clinical experience with Zarzio® in Europe: what have we learned?Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation G-CSF: filgrastim, lenograstim and biosimilars.Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question.Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis.Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.Follow-on biologics in oncology - the need for global and local regulations.Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.Biosimilar rhG-CSFs: how similar are they?Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.Extrapolation concept at work with biosimilar: a decade of experience in oncology.

P2860

Q35192785-8BB3E88D-FF85-4A36-B0E4-7193A583D64D Q35835005-015F1FCC-913A-4D27-BBE8-B8033BEEB367 Q38082542-1D50C5F5-2D8C-4024-B0F4-56B760A84555 Q38125609-1C54A7F8-2C8C-451A-B1FC-35FD4E2494C7 Q38186025-8E730958-2591-42BC-BB3E-463BCAC2923D Q38202661-F4406C73-5352-47CC-93A8-09B7B969A8CF Q38707629-A2B5BF84-249B-412F-AF91-2BB752E0DE40 Q38969947-D8E176FF-6823-422D-816A-EB06A22A156A Q39504419-D61953A9-6314-4F73-A975-D027BA6608F9 Q39900044-3942DD84-D73D-40AA-A389-92CC1385EE1B Q40402240-621CA11C-129C-4516-8F7E-818D5B081AB9 Q41547224-B8E42469-0371-4A1B-9F98-CA663E7266EE Q42267665-5622696E-3C7F-4383-BCEC-66F5D37FD445 Q43121123-F6C4E8F5-8BC6-43EA-9DD1-6A68F9741A14 Q43888363-4FC0AA4A-E953-40D1-9BA1-D5627D9EA678 Q44894394-50F8C2AC-FFD5-4F55-BBFD-3B360324A4E4 Q45788056-4492F8F6-E870-489F-9AB3-C282D8AB7905 Q51149892-E58F75F5-A519-4C30-9B79-D7DB6991F8EE Q53426777-04BF8DCD-2CDF-4DA8-A34E-B17F6113985B Q55384042-8532A42E-1509-41BA-9154-180432BC3D20

P2860

First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor

http://www.wikidata.org/entity/Q57217646

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в березні 2011

@uk

name

First experience of autologous ...... yte colony- stimulating factor

@en

First experience of autologous ...... yte colony- stimulating factor

@nl

type

label

First experience of autologous ...... yte colony- stimulating factor

@en

First experience of autologous ...... yte colony- stimulating factor

@nl

prefLabel

First experience of autologous ...... yte colony- stimulating factor

@en

First experience of autologous ...... yte colony- stimulating factor

@nl

P1433

Q57217646-F8FCF611-0E6D-454A-9AF3-B42B7E3F0D80

P1476

Q57217646-9453CE5E-7D98-46D0-8BA2-1CBA47382B8C

P2093

Q57217646-3354EEEA-95C1-44DE-A3B8-8C1238D3195B

Q57217646-49F6B717-C67F-4974-9F4C-304BC4001C68

Q57217646-521493E1-05E5-4734-9370-BB069874C203

Q57217646-656079E7-E013-455F-8814-C37497A8B56E

Q57217646-7D96BEED-15AD-4354-B512-EDFB7AB3B0F3

Q57217646-8AC8C344-80B1-44F7-82E4-4C3D2436CACD

Q57217646-923304F2-531C-4471-B480-20D6D5BAF800

Q57217646-E5436848-A476-48AE-9B19-E5C38C6B6B85

P2860

Q57217646-318B607F-102D-4F9A-ADDE-47F7F78E2BD3

Q57217646-6D319666-30C3-436A-BA53-29508065C9C0

Q57217646-80FF0909-AB0C-4524-9C45-3033BEED3B6E

Q57217646-840312D4-3BB7-4CD0-83B3-B6E4854842E8

Q57217646-95E8CE20-6353-4D88-A8F6-E057868E369F

Q57217646-A15CBD42-75A3-48D8-B398-44C9CFA88623

Q57217646-B2BC0DAB-290E-416F-A4D1-A44D09763734

Q57217646-B2CB522D-73A7-490C-951D-F2E0DA1B9E0A

Q57217646-BA0BF4AC-DBEF-4D95-82D3-DBEA1CDC64F4

Q57217646-BBC8498D-8DF6-4452-98EE-A7CA78016EB4

P2888

Q57217646-246155A5-C122-42D4-8EE7-AF27F5392CED

P304

Q57217646-383C5A80-CC09-4873-871D-7CDAC9CA4F4E

P31

Q57217646-2CF8E83B-B894-4E4D-BA6C-26843557577D

P356

Q57217646-BDE6BFBC-4945-4DA9-879F-FB9146577773

P407

Q57217646-AFA1A32D-5C2B-48D7-B0E3-76C5C0C7C21E

P433

Q57217646-8EEBB8AF-029B-4DAA-BDA0-D83E516E5ACD

P478

Q57217646-7AE106BB-E0CF-4654-B6E5-A09DD7111068

P50

Q57217646-8B4AE386-F4F0-412C-87C8-47029400B3A7

Q57217646-97AACE29-30DF-4371-8318-1C9789244446

P577

Q57217646-29441DA4-7D0A-4F01-84D2-289E402FB7BA

P698

Q57217646-6D55A5FA-4F8B-4A41-9D85-975CFBFFCC26

P356

S12325-011-0009-1

P1433

Advances in Therapy

P1476

First experience of autologous ...... yte colony- stimulating factor

@en

P2093

Anne-Colette Brignier

http://www.w3.org/2001/XMLSchema#string

Caroline Elie

http://www.w3.org/2001/XMLSchema#string

Charbel Aoun

http://www.w3.org/2001/XMLSchema#string

François Lefrère

http://www.w3.org/2001/XMLSchema#string

Jean-Antoine Ribeil

http://www.w3.org/2001/XMLSchema#string

Liliane Dal Cortivo

http://www.w3.org/2001/XMLSchema#string

Michael Bernimoulin

http://www.w3.org/2001/XMLSchema#string

Richard Delarue

http://www.w3.org/2001/XMLSchema#string

P2860

Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product.

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

The challenge of biosimilars.

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

Current treatment strategy of diffuse large B-cell lymphomas.

Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management.

Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma.

XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.

P2888

s12325-011-0009-1

P304

304-310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-011-0009-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Marina Cavazzana-Calvo

Olivier Hermine

P577

2011-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21400232

http://www.w3.org/2001/XMLSchema#string